Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 11 for:    preterm hypothermia encephalopathy

Long Term Prognostic of Neonatal Hypoxic Ischemic Encephalopathy With Hypothermia Treatment (LyTONEPAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02676063
Recruitment Status : Active, not recruiting
First Posted : February 8, 2016
Last Update Posted : June 6, 2018
Sponsor:
Information provided by (Responsible Party):
University Hospital, Grenoble

Brief Summary:

The primary objective is to evaluate neonatal characteristics, and biological and clinical investigations as predictive factors of death, or of severe and moderate neurodevelopmental disability at 3 years, in a large population-based cohort of full-term and late preterm neonates with moderate or severe HIE.

Contrary to most previous studies which have often analyzed the accuracy of one factor among all other clinical investigations, the investigators objective's is to seek a relevant combination of several factors among the following list:

  • Neonatal characteristics: gestational age and birthweight, maternal disease, acute intrapartum event, delivery mode, acidosis, neurological examination, place of birth and neonatal transfer
  • Laboratory investigations: pH, lactates and new biological markers as detailed below
  • Clinical investigations: aEEG, EEG, MRI, diffusion-weighted MRI

Condition or disease
Ischemic-Hypoxic Encephalopathy

Detailed Description:

Hypoxic-ischemic encephalopathy (HIE) is a rare neonatal condition affecting about 1‰ births and with a high rate of death and severe neurological disability despite significant improvement of the management of this illness in the last ten years. During the first hours and days of life, different examinations are made by neonatologists to guide decisions about the management of HIE and to provide information to families. Nevertheless, better knowledge about the early and late predictive factors of long-term severe and moderate neurodevelopmental outcomes is badly needed.

This study is a prospective national observational population-based study involving all level III intensive care units in France.

This population-based cohort study will be performed including all moderate or severe cases of HIE, occurring between 34 and 42 completed weeks gestation in newborns admitted to a neonatal intensive care unit of the participating French regions. Children will be followed-up until the age of 3 years.

Participating centers will be invited to adhere to current HIE management guidelines and/or clinical investigations considered optimal to date, to ensure standardize clinical practice. The study will ensure high quality data collection.

About indications, timing and characteristics of treatments and investigations will be elaborated by the scientific committee during the preparation stage of the cohort study. This professional advice will have the double advantage of enabling us to record more homogeneous and high-quality data, and to standardize and improve clinical management and investigations among newborns with HIE.

Within this main study, an ancillary study will be performed by 21 centers to address the first secondary objective (predictive value of very early - first 6 hours of life - neurological examination and biological investigations, including specific new biomarkers such as Interleukin-6, Metalloproteinase-9, TIMP-1, Albumin modified by hypoxia, troponin I, acylcarnitins and amino acids).

Layout table for study information
Study Type : Observational
Estimated Enrollment : 800 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long Term Prognostic of Neonatal Hypoxic Ischemic Encephalopathy in the Era of Neuroprotective Treatment With Hypothermia
Actual Study Start Date : September 2015
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hypothermia

Group/Cohort
neonatal Hypoxic Ischemic encephalopathy
moderate or severe HIE among term and late preterm newborn



Primary Outcome Measures :
  1. The primary outcome measure is a combined criterion : death, neurodevelopmental disabilities in survivors [ Time Frame: between birth and 3 years of age ]

    A combined criterion which includes:

    • Death between birth and 3 years of age
    • Neurodevelopmental disabilities in survivors, defined as :

      o Severe disabilities

    • Intellectual impairment with a mental score >2SD below the mean or <70 (ASQ)
    • Or Cerebral palsy with a Gross Motor Function level of 3-5 according to the GMFCS
    • Or bilateral blindness (vision <20/200 acuity)
    • Or deafness requiring amplification (>60dB)and/
    • Or a persistent disorder defined as recurrent seizures after discharge from neonatal intensive care requiring anti-convulsion therapy at the examination time point

      o Moderate disabilities

    • Intellectual impairment with a mental score >1SD below the mean or 70 to 84 (ASQ)
    • Cerebral palsy with a Gross Motor Function level of 1 or 2 according to the GMFCS
    • Or hearing impairment requiring no amplification


Secondary Outcome Measures :
  1. First secondary objective : The relevance of specific new biomarkers : Protein levels (IL-6, MMP-9, TIMP-1, Albumine modified by hypoxia, troponine I), acylcarnitins and amino acids. [ Time Frame: before H6 and at 3 days ]

    The biologist will evaluate the relevance of specific new biomarkers :

    • Protein levels (IL-6, MMP-9, TIMP-1, Albumine modified by hypoxia, troponine I) unites will be determined using an ELISA
    • the measurement of acylcarnitins and amino acids by tandem liquid phase chromatography coupled with mass spectroscopy.

    The analyses will be blinded and centralized to Reims University laboratory


  2. Second secondary objective: the predictive value of clinical investigations during the first weeks of life and treatments. [ Time Frame: first week, At 18 months and 3 years of age ]

    To analyze the predictive value of clinical investigations during the first weeks of life and treatments, including cooling:

    • for normal outcomes (absence of death, any disability, any epilepsy or any need for physiotherapy, orthophonist or psychologist or other measures of reeducation), moderate or severe neurodevelopmental disabilities, and death
    • At 18 months and 3 years of age
    • In this part, we will assess the ability of a normal developmental assessment at 18 months to predict survival free of disability or retardation at 3 years. This information will be useful in the future to define different strategies of follow up according to the assessment at 18 months of age.

  3. Third secondary objective : Number and percentage of participants with cooling. [ Time Frame: birth ]

    The third secondary objective is analyzed thanks to :

    • number of patients with method of cooling : Criticool, tecotherm, craft, other
    • duration of cooling in hours
    • number of severe or modere HIE according to the Sarnat classification
    • time to initiate cooling in minutes

  4. Fourth secondary objective : Number and percentage of various obstetrical conditions leading to the worse outcomes [ Time Frame: birth ]

    Number and percentage of :

    • Maternal pyrexia,
    • a persistent occipito-posterior position,
    • an acute intrapartum event (hemorrhage, maternal convulsions, rupture of uterus, snapped cord, and birth of baby before arrival at obstetric facility),
    • an instrumental vaginal delivery
    • an emergency caesarean section



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study will be performed on all moderate or severe cases of hypoxic ischemic encephalopathyhie, occurring between 34 and 42 completed weeks gestation in newborns admitted to a neonatal intensive care unit of the participating French regions. Children will be followed-up until the age of 3 years.
Criteria

Inclusion Criteria:

  • Infants born at a gestational age of 34 weeks or more;
  • Presenting early neurological distress with clinical signs of moderate to severe HIE at a standardized neurologic examination performed by a senior examiner:

    • Moderate HIE: lethargy, hyper-reflexia, miosis, bradycardia, seizures, hypotonia with weak suck and Moro reflex
    • Severe HIE: stupor, flaccidity, small to mid-position pupils that react poorly to light, reduced stretch reflexes, hypothermia or no Moro reflex
  • With criteria for asphyxia:

    • pH of 7.0 or less or a base deficit of 16 mmol per liter or more in a sample of umbilical-cord blood or any blood sampled in the first hour after birth.
    • If, during this interval, the pH is between 7.01 and 7.15, base deficit is between 10 and 15.9 mmol per liter, or blood gas is not available, additional criteria will be required. These include:
    • an acute perinatal event (e.g., late or variable decelerations, cord prolapse, cord rupture, uterine rupture, maternal trauma, hemorrhage, or cardiorespiratory arrest)
    • or an abrupt change in fetal heart rate (FHR), defined as a persistent abnormal FHE after a period of normal tracing: bradycardia or prolonged deceleration, persistent variable decelerations, persistent late decelerations, and reduced heart variability
    • or either a 10-minute Apgar score of 5 or less or assisted ventilation initiated at birth and continued for at least 10 minutes.
  • Written parental informed consent
  • Covered by the French social security

Exclusion Criteria:

  • Congenital malformations
  • Chromosomal disorders
  • Congenital neuromuscular disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02676063


Locations
Show Show 22 study locations
Sponsors and Collaborators
University Hospital, Grenoble
Investigators
Layout table for investigator information
Principal Investigator: Thierry DEBILLON, MD PhD University Hospital, Grenoble
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University Hospital, Grenoble
ClinicalTrials.gov Identifier: NCT02676063    
Other Study ID Numbers: DCIC1416
First Posted: February 8, 2016    Key Record Dates
Last Update Posted: June 6, 2018
Last Verified: June 2018
Keywords provided by University Hospital, Grenoble:
predictive factors
neurodevelopmental disabilities
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypothermia
Brain Diseases
Brain Ischemia
Hypoxia-Ischemia, Brain
Hypoxia, Brain
Ischemia
Hypoxia
Pathologic Processes
Central Nervous System Diseases
Nervous System Diseases
Body Temperature Changes
Signs and Symptoms, Respiratory
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases